The Evaluation of Effectiveness and Safety for New Therapy with Bone Marrow derived Autologous Mesenchymal Stem Cell for Hepatic Failure caused by Alcoholic Liver Cirrhosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0000266

Enrollment

Registered

2011-11-11

Start date

2009-09-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine : Hepatic artery catheterization and injection with mesenchymal stem cell will be used in enrolled patients through right femoral artery at 0month and 1month, respectively.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Alcoholic liver cirrhosis(child Pugh class B or C, = 7 scores) , confirmed by clinically or biopsy. (2) Stop drinking over past 6months. (3) Patients agree with informed consent Patients must satisfy all inclusion criteria.

Exclusion criteria

Exclusion criteria: (1) Patients who did not satisfy inclusion criteria (2) Hepatocellular carcinoma (3) Pregnancy or breast feeding (4) Infective disease(HIV, HBV, HCV..) (5) Other incurable malignancy

Design outcomes

Primary

Measure	Time frame
Improvement of liver cirrhosis ;Improvement of portal hypertension	—

Secondary

Measure	Time frame
Liver cirrhosis fibrosis grade;Liver mesenchymal cell activity evaluation by immunohistochemistry;Hydroxyproline;Real-Time Polymerase Chain Reaction (TGF-beta, collagen, procollagen, MMP2 or 9);Hepatic vein pressure gradient;Hepatic vein arrival time;Fibroscan;Child-Pugh' score;MELD score;Change of acites	—

Countries

Korea, Republic of

Contacts

Public ContactMoon Kim

Yonsei University, Wonju Severance Christian Hospital

Outcome results